Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment

A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up

(2013) Jacqueline Trouillas et al.   ACTA NEUROPATHOLOGICA

DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors

(2013) Toshio Hirohata et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in Nonfunctioning Pituitary Adenomas: A High Throughput TMA, Immunohistochemical Study

(2012) Claudia Ramírez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status

(2011) Ann I. McCormack et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

(2011) Hidenori Fukuoka et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-VEGF therapy in pituitary carcinoma

(2011) Leon D. Ortiz et al.   Pituitary

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

(2010) Marco Losa et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases

(2010) H. Bode et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression

(2010) Zachary M. Bush et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy

(2010) Troy H. Dillard et al.   Pituitary

High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease

(2009) Akira Takeshita et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor

(2009) Marie S. Thearle et al.   Pituitary

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

(2008) Monika E. Hegi et al.   JOURNAL OF CLINICAL ONCOLOGY

Focal radiation therapy for patients with persistent/recurrent pituitary adenoma, despite previous radiotherapy

(2008) Albert A. Edwards et al.   Pituitary